In this context, erlotinib, gefitinib and afatinib are known to be substrates of the ATP‐binding cassette transporter ABCB1 (also known as P‐glycoprotein or MDR1) [32], a major transporter involved in drug resistance in cancer [31]. Here, ABCA4 is linked to cancer.